HLB Group to Present Research Results from Oncology Pipelines of Two Affiliates at AACR

Verismo to Present Interim Results from U.S. Phase 1 Trial of SynKIR-110
Elevar to Announce Research Findings on Lerafugratinib

On March 13, HLB Group announced that it will present the latest research results from its key oncology pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2026, the world’s largest cancer conference, to be held in San Diego, United States from April 17 to 22.

The AACR is recognized as one of the world’s three major cancer conferences, alongside the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO). The event brings together cancer researchers, as well as pharmaceutical and biotech companies from around the globe, to share the most recent advancements in cancer research.

Verismo Therapeutics, the U.S. subsidiary of HLB Innovation, plans to present interim results from the Phase 1 clinical trial in the United States for its chimeric antigen receptor T-cell (CAR-T) therapy ‘SynKIR-110’ targeting solid tumors at the upcoming AACR. SynKIR-110 is a therapy developed based on Verismo’s proprietary ‘KIR-CAR’ platform technology. It is designed to overcome the problem of T-cell exhaustion caused by excessive T-cell activation, which has been a challenge with conventional CAR-T therapies.

HLB’s subsidiary Elevar will also release an analysis comparing the selectivity of the FGFR2-targeted cancer therapy ‘Lerafugratinib’ to existing pan-FGFR inhibitors. Lerafugratinib demonstrated efficacy and safety in global Phase 2 clinical trial data presented at the ASCO Gastrointestinal Cancers Symposium (ASCO GI 2026) in January. Designated as an innovative therapy in 2023, Lerafugratinib’s application for approval was submitted to the U.S. Food and Drug Administration (FDA) in January based on these Phase 2 clinical results.

Kyung Sook Nam, Executive Director of Bio Strategy Planning at HLB Group, said, “Through our presentations at this year’s AACR, we plan to demonstrate the technological differentiation and clinical value of HLB Group’s next-generation oncology pipeline in the global market. Based on validated data, we will further refine our global development strategies and accelerate clinical progress to secure sustainable technological competitiveness in the next-generation oncology field.”

This content was produced with the assistance of AI translation services.